Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications
Gail Lewis Phillips
Springer Science & Business Media, Dec 13, 2012 - Medical - 378 pages
This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to ...
Gail Lewis Phillips
No preview available - 2015
affinity anti anti-PSMA antibody-drug conjugate anticancer antigen antitumor activity assay assessed auristatin B-cell binding Bioconjug Chem Biol breast cancer brentuximab vedotin calicheamicin cancer cells carcinoma cell lines cell surface characterization chemotherapy cleavable Clin Cancer Res Clin Oncol clinical trials conjugate cytotoxic cytotoxic agent disease disulfide domain dose doxorubicin drug conjugate effect effector efficacy EphA2 evaluated expression GPNMB growth HER2 HER2/neu human immunoconjugate immunogenicity Immunol immunotoxins inhibition intracellular kinase Lambert JM lapatinib leukemia levels linker lorvotuzumab mertansine lymphoma lysosomal malignancies maytansine maytansinoid median membrane antigen metabolites metastatic breast cancer mg/kg mice microtubule MMAE models moiety molecule monoclonal antibody objective response ovarian cancer ozogamicin patients payload pharmacokinetics Phase I study plasma potential Pre-Clinical Development preclinical prostate cancer protein PSMA receptor recombinant release ricin rituximab safety scFv solid tumors specific study TDM4258g target therapeutic tissues toxicity toxin trastuzumab trastuzumab-DM1 treatment tumor tumor cells vitro vivo xenografts